LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK), a research-based pharmaceutical and healthcare company, and Valeant Pharmaceuticals International (VRX) said Monday that, on Oct. 30, they filed a new drug application with the U.S. Food and Drug Administration and a marketing authorisation application with the European Medicines Agency, for retigabine, used as adjunctive therapy to treat adult epilepsy patients with partial-onset seizures.
MAIN FACTS:
-Retigabine is not approved or licensed anywhere in the world.
-By London Bureau, Dow Jones Newswires; Contact Ian Walker; +44 (0)20 7842 9296; ian.walker@dowjones.com